Does the media favor UPXI or BCYC?

In the previous week, Bicycle Therapeutics had 4 more articles in the media than Upexi. MarketBeat recorded 5 mentions for Bicycle Therapeutics and 1 mentions for Upexi. Upexi's average media sentiment score of 0.00 beat Bicycle Therapeutics' score of -0.24 indicating that Upexi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, IMRX or UPXI?

Upexi has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A Upexi $26.14M 2.45 -$13.68M -$0.62 N/A

Is IMRX or UPXI more profitable?

Immuneering has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Immuneering's return on equity of -26.32% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -26.32% -24.98% Upexi -874.00% -66.70% -19.56%

Does the media refer more to IMRX or UPXI?

In the previous week, Immuneering had 9 more articles in the media than Upexi. MarketBeat recorded 10 mentions for Immuneering and 1 mentions for Upexi. Immuneering's average media sentiment score of 0.25 beat Upexi's score of 0.00 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upexi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TKNO or UPXI more profitable?

Alpha Teknova has a net margin of -38.37% compared to Upexi's net margin of -874.00%. Alpha Teknova's return on equity of -24.38% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Teknova -38.37% -24.38% -16.24% Upexi -874.00% -66.70% -19.56%

Does the media refer more to TKNO or UPXI?

In the previous week, Alpha Teknova had 8 more articles in the media than Upexi. MarketBeat recorded 9 mentions for Alpha Teknova and 1 mentions for Upexi. Alpha Teknova's average media sentiment score of 0.23 beat Upexi's score of 0.00 indicating that Alpha Teknova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Teknova 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Upexi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, UPXI or FATE?

Upexi has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $26.14M 2.45 -$13.68M -$0.62 N/A Fate Therapeutics $6.65M 43.64 -$136.32M -$1.09 N/A

Is UPXI or FATE more profitable?

Upexi has a net margin of -874.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Fate Therapeutics -2,056.79% -58.89% -39.39%

Does the media prefer UPXI or FATE?

In the previous week, Fate Therapeutics had 1 more articles in the media than Upexi. MarketBeat recorded 2 mentions for Fate Therapeutics and 1 mentions for Upexi. Fate Therapeutics' average media sentiment score of 0.60 beat Upexi's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, UPXI or ALXO?

Upexi has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $26.14M 2.45 -$13.68M -$0.62 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is UPXI or ALXO more profitable?

ALX Oncology has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% ALX Oncology N/A -124.06% -85.57%

Does the media prefer UPXI or ALXO?

In the previous week, ALX Oncology had 3 more articles in the media than Upexi. MarketBeat recorded 4 mentions for ALX Oncology and 1 mentions for Upexi. ALX Oncology's average media sentiment score of 1.19 beat Upexi's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Upexi (UPXI) Competitors

$0.81 -0.03 (-3.76%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 +0.00 (+0.22%)

As of 06:20 PM Eastern

Compare

UPXI vs. BCYC, IMRX, TKNO, FATE, and ALXO

Should you buy Upexi stock or one of its competitors? MarketBeat compares Upexi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upexi include Bicycle Therapeutics (BCYC), Immuneering (IMRX), Alpha Teknova (TKNO), Fate Therapeutics (FATE), and ALX Oncology (ALXO).

How does Upexi compare to Bicycle Therapeutics?

Upexi (NASDAQ:UPXI) and Bicycle Therapeutics (NASDAQ:BCYC) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Bicycle Therapeutics has a net margin of -311.11% compared to Upexi's net margin of -874.00%. Bicycle Therapeutics' return on equity of -33.22% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

In the previous week, Bicycle Therapeutics had 4 more articles in the media than Upexi. MarketBeat recorded 5 mentions for Bicycle Therapeutics and 1 mentions for Upexi. Upexi's average media sentiment score of 0.00 beat Bicycle Therapeutics' score of -0.24 indicating that Upexi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Upexi presently has a consensus target price of $4.65, indicating a potential upside of 471.82%. Bicycle Therapeutics has a consensus target price of $13.86, indicating a potential upside of 249.05%. Given Upexi's higher possible upside, analysts clearly believe Upexi is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Upexi has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$26.14M	2.45	-$13.68M	-$0.62	N/A
Bicycle Therapeutics	$72.86M	3.80	-$218.96M	-$2.73	N/A

5.7% of Upexi shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 9.0% of Upexi shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Upexi has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

Summary

Bicycle Therapeutics beats Upexi on 10 of the 16 factors compared between the two stocks.

How does Upexi compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Upexi (NASDAQ:UPXI) are related small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Immuneering currently has a consensus target price of $17.50, indicating a potential upside of 292.38%. Upexi has a consensus target price of $4.65, indicating a potential upside of 471.82%. Given Upexi's higher possible upside, analysts plainly believe Upexi is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 14.9% of Immuneering shares are owned by insiders. Comparatively, 9.0% of Upexi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immuneering has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Immuneering's return on equity of -26.32% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-26.32%	-24.98%
Upexi	-874.00%	-66.70%	-19.56%

In the previous week, Immuneering had 9 more articles in the media than Upexi. MarketBeat recorded 10 mentions for Immuneering and 1 mentions for Upexi. Immuneering's average media sentiment score of 0.25 beat Upexi's score of 0.00 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Upexi has a beta of -0.27, meaning that its share price is 127% less volatile than the broader market.

Upexi has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Upexi	$26.14M	2.45	-$13.68M	-$0.62	N/A

Summary

Immuneering beats Upexi on 10 of the 16 factors compared between the two stocks.

How does Upexi compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Upexi (NASDAQ:UPXI) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Upexi has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	8.64	-$17.26M	-$0.32	N/A
Upexi	$26.14M	2.45	-$13.68M	-$0.62	N/A

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by insiders. Comparatively, 9.0% of Upexi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alpha Teknova has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Upexi has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market.

In the previous week, Alpha Teknova had 8 more articles in the media than Upexi. MarketBeat recorded 9 mentions for Alpha Teknova and 1 mentions for Upexi. Alpha Teknova's average media sentiment score of 0.23 beat Upexi's score of 0.00 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Teknova	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Teknova currently has a consensus target price of $7.00, indicating a potential upside of 7.20%. Upexi has a consensus target price of $4.65, indicating a potential upside of 471.82%. Given Upexi's higher probable upside, analysts clearly believe Upexi is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alpha Teknova has a net margin of -38.37% compared to Upexi's net margin of -874.00%. Alpha Teknova's return on equity of -24.38% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.38%	-16.24%
Upexi	-874.00%	-66.70%	-19.56%

Summary

Alpha Teknova beats Upexi on 11 of the 14 factors compared between the two stocks.

How does Upexi compare to Fate Therapeutics?

Upexi (NASDAQ:UPXI) and Fate Therapeutics (NASDAQ:FATE) are related small-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Fate Therapeutics had 1 more articles in the media than Upexi. MarketBeat recorded 2 mentions for Fate Therapeutics and 1 mentions for Upexi. Fate Therapeutics' average media sentiment score of 0.60 beat Upexi's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Upexi has a net margin of -874.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Upexi has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 9.0% of Upexi shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Upexi has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$26.14M	2.45	-$13.68M	-$0.62	N/A
Fate Therapeutics	$6.65M	43.64	-$136.32M	-$1.09	N/A

Upexi presently has a consensus price target of $4.65, suggesting a potential upside of 471.82%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 105.82%. Given Upexi's higher probable upside, equities research analysts clearly believe Upexi is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Upexi and Fate Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Upexi compare to ALX Oncology?

Upexi (NASDAQ:UPXI) and ALX Oncology (NASDAQ:ALXO) are related small-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Upexi has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$26.14M	2.45	-$13.68M	-$0.62	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

ALX Oncology has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
ALX Oncology	N/A	-124.06%	-85.57%

5.7% of Upexi shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 9.0% of Upexi shares are owned by insiders. Comparatively, 12.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Upexi presently has a consensus price target of $4.65, indicating a potential upside of 471.82%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 118.01%. Given Upexi's higher possible upside, research analysts plainly believe Upexi is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Upexi has a beta of -0.27, suggesting that its share price is 127% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

In the previous week, ALX Oncology had 3 more articles in the media than Upexi. MarketBeat recorded 4 mentions for ALX Oncology and 1 mentions for Upexi. ALX Oncology's average media sentiment score of 1.19 beat Upexi's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ALX Oncology beats Upexi on 8 of the 15 factors compared between the two stocks.

Get Upexi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPXI vs. The Competition

Export

Metric	Upexi	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$66.50M	$27.64B	$14.07B	$12.87B
Dividend Yield	N/A	5.79%	5.92%	9.94%
P/E Ratio	-1.31	18.00	29.31	25.30
Price / Sales	2.45	386.55	512.74	82.63
Price / Cash	N/A	162.44	39.25	50.37
Price / Book	0.81	3.22	3.72	6.13
Net Income	-$13.68M	$1.08B	$1.31B	$342.95M
7 Day Performance	0.38%	0.93%	1.13%	3.03%
1 Month Performance	-7.69%	-2.55%	0.48%	-3.04%
1 Year Performance	-85.50%	-8.88%	13.19%	20.65%

Upexi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPXI Upexi	1.3394 of 5 stars	$0.81 -3.8%	$4.65 +471.8%	-84.0%	$66.50M	$26.14M	N/A	130	Gap Down
BCYC Bicycle Therapeutics	2.8059 of 5 stars	$3.94 -0.3%	$14.00 +255.3%	-49.5%	$275.06M	$63.50M	N/A	240	Earnings Report Upcoming Earnings
IMRX Immuneering	2.8322 of 5 stars	$4.24 -2.8%	$17.57 +314.4%	+23.0%	$274.33M	N/A	N/A	60	Trending News Earnings Report Analyst Upgrade Gap Up
TKNO Alpha Teknova	0.9345 of 5 stars	$5.09 +4.9%	N/A	+30.5%	$272.90M	$41.80M	N/A	240	News Coverage Earnings Report Analyst Forecast
FATE Fate Therapeutics	3.1821 of 5 stars	$2.32 -4.5%	$5.13 +120.9%	+140.7%	$270.42M	$6.65M	N/A	550	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPXI) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upexi (UPXI) Competitors

UPXI vs. BCYC, IMRX, TKNO, FATE, and ALXO

How does Upexi compare to Bicycle Therapeutics?

Summary

How does Upexi compare to Immuneering?

Summary

How does Upexi compare to Alpha Teknova?

Summary

How does Upexi compare to Fate Therapeutics?

Summary

How does Upexi compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upexi (UPXI) Competitors

UPXI vs. BCYC, IMRX, TKNO, FATE, and ALXO

How does Upexi compare to Bicycle Therapeutics?

Is UPXI or BCYC more profitable?

Does the media favor UPXI or BCYC?

Do analysts prefer UPXI or BCYC?

Which has preferable valuation & earnings, UPXI or BCYC?

Do insiders and institutionals believe in UPXI or BCYC?

Which has more volatility and risk, UPXI or BCYC?

Summary

How does Upexi compare to Immuneering?

Do analysts recommend IMRX or UPXI?

Do insiders & institutionals have more ownership in IMRX or UPXI?

Is IMRX or UPXI more profitable?

Does the media refer more to IMRX or UPXI?

Which has more risk & volatility, IMRX or UPXI?

Which has preferable valuation & earnings, IMRX or UPXI?

Summary

How does Upexi compare to Alpha Teknova?

Which has better earnings & valuation, TKNO or UPXI?

Do insiders & institutionals have more ownership in TKNO or UPXI?

Which has more risk and volatility, TKNO or UPXI?

Does the media refer more to TKNO or UPXI?

Do analysts recommend TKNO or UPXI?

Is TKNO or UPXI more profitable?

Summary

How does Upexi compare to Fate Therapeutics?

Does the media prefer UPXI or FATE?

Is UPXI or FATE more profitable?

Which has more volatility and risk, UPXI or FATE?

Do insiders & institutionals have more ownership in UPXI or FATE?

Which has stronger valuation and earnings, UPXI or FATE?

Do analysts recommend UPXI or FATE?

Summary

How does Upexi compare to ALX Oncology?

Which has higher valuation and earnings, UPXI or ALXO?

Is UPXI or ALXO more profitable?

Do insiders & institutionals have more ownership in UPXI or ALXO?

Do analysts rate UPXI or ALXO?

Which has more volatility and risk, UPXI or ALXO?

Does the media prefer UPXI or ALXO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools